Clinical Trial Update: A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety and efficacy study of CNTO-328 (siltuximab) in patients with B-cell non-Hodgkin lymphoma, multiple myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castleman Disease
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• CNTO 328

Snippet

Sponsor: Centocor, Inc. | Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 1 | Status: COMPLETED